West Pharma (WST) Misses Q2 EPS by 22c; cuts guidance
Tweet
Share
E-mailGet Alerts WST Hot Sheet
Price: $328.10 +0.05%
Revenue Growth %: +9.5%
Financial Fact:
Cost of goods and services sold: 255.6M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +9.5%
Financial Fact:
Cost of goods and services sold: 255.6M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
West Pharma (NYSE: WST) reported Q2 EPS of $1.52, $0.22 worse than the analyst estimate of $1.74. Revenue for the quarter came in at $702.1 million versus the consensus estimate of $729.36 million.
GUIDANCE:
West Pharma sees FY2024 EPS of $6.35-$6.65, versus the consensus of $7.74. West Pharma sees FY2024 revenue of $2.87-2.9 million, versus the consensus of $3.01 million.
For earnings history and earnings-related data on West Pharma (WST) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- AeroVironment restates quarterly financials, citing $89M goodwill error
- Trump's CDC nominee to exit UnitedHealth, divest holdings
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
